Actas dermo-sifiliograficas · 2026
Adverse events associated with topical corticosteroid use in moderate-to-severe atopic dermatitis: a prospective analysis from the BIOBADATOP registry.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Díaz-Calvillo P, Ruiz-Villaverde R, Silvestre-Salvador J F, Espasandín-Arias M, Rodríguez-Serna M, Gonzalez-Quesada A, Gilaberte-Calzada Y, Mauleón-Fernández C, Chicharro P, Pereyra-Rodríguez J J, Herrera-Acosta E, Montero-Vilchez T, Elosua-González M, Curto-Barredo L, García-Doval I, Descalzo-Gallego M Á, Carrascosa J M, Grupo BIOBADATOP Group
Аннотация
The long-term safety of topical corticosteroids (TCS) in atopic dermatitis (AD) continues to generate uncertainty and has been identified as a research priority. This study aimed to prospectively evaluate adverse events (AEs) associated with TCS use in the BIOBADATOP registry. A total of 660 patients were included, of whom 484 (73.3%) used TCS at baseline and/or during follow-up. The median baseline EASI score was 21, and baseline disease severity was similar between TCS users and non-users. During TCS treatment, AEs were reported in 4 of 484 patients (0.8%; 95%CI, 0.2-2.1%), all of which were mild: striae, pityriasis sicca of the scalp, hypertension, and mild hypertriglyceridemia. These real-world findings support the safety profile of TCS and make it difficult to justify descriptions of large populations as being intolerant to, or at increased risk from, TCS.